Key Highlights

  • Patrys shares touched a 52-week low during the session on Monday 9 November 2026 and closed at $0.02, down 9.09%.
  • All four Cohort 1 participants in the RLS-2202 Phase 1a trial completed dosing.
  • Cash at the end of the September quarter was A$2.23 million, with an R&D tax refund of about A$620,000 expected.

Patrys Ltd (ASX:PAB) touched a 52-week low during the Trading session on Monday, 9 November 2026, and closed at $0.02, down 9.09%. Patrys is a clinical-stage reformulation and antibody development company, and its lead program is RLS-2202.

Latest Development: Quarterly Report, 29 October 2026

Patrys released its quarterly activities report on 29 October 2026. The company said human research ethics approval was secured and first participants were dosed in the RLS-2202 Phase 1a trial at CMAX.

All four Cohort 1 participants completed dosing, follow-up and planned clinical assessments. After quarter end, the Safety Review Committee found Cohort 1 had an acceptable safety and tolerability profile and recommended advancing to Cohort 2.

The company also signed a binding agreement with Yale University, securing entitlement to 50% of future commercialisation Revenue Yale receives from the deoxymab intellectual property portfolio.

About the Company

Patrys develops antibody-based therapies and reformulations, and it has established an International Clinical Advisory Committee to guide clinical development.

Sector Context

Early-stage clinical programs carry a high rate of attrition, and cohort-by-cohort safety reviews are a standard step before larger studies.

Risks and What to Watch Ahead

The program is at an early Phase 1a stage, and results remain subject to later clinical trial outcomes. Cash at quarter end was A$2.23 million.

Watch items include Cohort 2 progress, the R&D tax refund and funding plans.

Final Word

Patrys' report describes completed Cohort 1 dosing, a recommendation to advance to Cohort 2 and a licence arrangement with Yale, alongside a modest cash balance.